2021
DOI: 10.3389/fonc.2021.684025
|View full text |Cite
|
Sign up to set email alerts
|

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma

Abstract: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as CD274 (PD-L1) in lung and other solid cancers. However, only a small subset of MPM patients respond to checkpoint inhibition, and this response has been varied and unpredictable across several clinical trials. Recent advances in next-generation s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 52 publications
0
5
0
Order By: Relevance
“…In the study, a higher number of PD-1 + CTLA-4 + CD8 + T cells was found in a subtype and more ICOS + -CTLA4 + T-regs and PD-1 + TAMs in the other one, suggesting a different response to immune-checkpoint inhibitors (ICIs) [ 130 ]. Additionally, increased macrophage infiltration was detected in the non-epithelioid MPM and a high ratio CD8 + /CD68 + was correlated with a worse prognosis [ 34 , 131 ]. Non-epithelioid subtypes were also associated with PD-L2 positivity, and they were more likely to have a high infiltration with TIM3+ lymphocytes.…”
Section: Intra-tumor Heterogeneity Within Mpm Subtypes and Tmementioning
confidence: 99%
“…In the study, a higher number of PD-1 + CTLA-4 + CD8 + T cells was found in a subtype and more ICOS + -CTLA4 + T-regs and PD-1 + TAMs in the other one, suggesting a different response to immune-checkpoint inhibitors (ICIs) [ 130 ]. Additionally, increased macrophage infiltration was detected in the non-epithelioid MPM and a high ratio CD8 + /CD68 + was correlated with a worse prognosis [ 34 , 131 ]. Non-epithelioid subtypes were also associated with PD-L2 positivity, and they were more likely to have a high infiltration with TIM3+ lymphocytes.…”
Section: Intra-tumor Heterogeneity Within Mpm Subtypes and Tmementioning
confidence: 99%
“…So far, the development of malignant mesothelioma in patients is mostly attributed to asbestos exposure. Asbestos fibers can cause chronic inflammation over time, leading to immune activation, inflammatory microenvironment, and changes in the genome and epigenome conducive to malignant transformation [ 6 ]. Additionally, pathogenesis of mesothelioma can be driven by a dysregulated translatome, as shown by polysome profiling [ 41 ].…”
Section: Discussionmentioning
confidence: 99%
“…For example, a recent study has shown differences in the internal morphology of asbestos ferruginous bodies (AFBs), which are a key indicator of asbestos-induced malignant mesothelioma, between smokers and non-smokers [ 4 ]. Recent advances in high-throughput technologies have helped reveal molecular cues, including genomic and epigenetic factors and their interplay with the immune response, that are relevant to mesothelioma development [ 5 , 6 ]. Additionally, preclinical models of mesothelioma have been useful in deciphering the disease’s pathogenesis and in developing new clinical interventions [ 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…These results are consistent with reports of frequent association of PD-L1 protein expression and sarcomatoid mesotheliomas, poor prognosis, and increased lymphocytic inflammation. [78][79][80][81][82][83][84][85] TRAF mutations have been described in localized pleural mesothelioma 86 and in adenomatoid tumors of the genital tract 87 but have not yet been identified in thoracic adenomatoid tumors, although these are exceedingly rare with less than 20 reported in the thoracic region. [88][89][90] BAP1 mutations and genomic near haploidization have also been described in localized pleural mesothelioma.…”
Section: Differential Diagnoses Of Diffuse Pleural Mesothelioma: Thor...mentioning
confidence: 99%